Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Invectys

Request full access

Developing innovative approaches to immunotherapy to treat cancer

Paris, FranceFounded 2010Biotech & Life Sciences

About Invectys

Invectys is a biopharmaceutical company founded in 2010 by Pierre Langlade Demoyen and Simon Wain-Hobson, focused on the development of immunotherapy approaches for cancer treatment.

Pierre Langlade Demoyen, who serves as the CEO, has a background in immunology and has been involved in the development of therapeutic vaccines. Simon Wain-Hobson is a virologist and a member of the French Academy of Sciences, bringing extensive research experience to the company. Their combined expertise in immunology and virology forms the foundation of Invectys' scientific approach.

The company's core technology revolves around telomerase, an enzyme that is overexpressed in most cancer cells. Invectys is developing therapeutic vaccines that stimulate the immune system to recognize and attack cancer cells that express telomerase. This approach aims to provide a broadly applicable treatment for various types of cancer.

Invectys has developed a platform of products, including DNA-based vaccines, which are designed to trigger a cellular immune response against tumors. The company is advancing its product candidates through clinical trials to evaluate their safety and efficacy in cancer patients.

The business operates in the oncology market, a segment of the healthcare industry with a high demand for new treatment options. Invectys' business model is centered on the research and development of its proprietary technology, with the goal of commercializing its therapeutic vaccines through partnerships with larger pharmaceutical companies or by bringing them to market independently. The company has secured funding from private investors to support its research and clinical development activities.

Source: Dealroom company data

At a glance

Status
Operational
Employees
12
Open positions
None listed
Dealroom signal
63.2/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Oncology, Immune System, Spinout, Biotech and Pharma, Hard Tech, radar de l'innovation, DT and LS, observatoire healthtech, science-based
Business model
Manufacturing

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
DEBTDebt Oct 2024 $4M — Undisclosed ↗
GRANTOther financing May 2020 $14M — Undisclosed —
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Invectys website traffic

Latest recorded traffic for Invectys is 1.1K monthly website visits, down 64.5% over the last three months. Invectys's team declined 36.8% over the past year.

Latest monthly visits1.1K 3-month web change-64.5% 1-year team growth-36.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Invectys in the Paris ecosystem

Live from Dealroom

The Invectys office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Other known investors1 additional known investor

  • Institut Pasteur
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Invectys’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.